Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvae071 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Marc P Bonaca und 9 weiteren Autor:innen. Beteiligte Einrichtung: CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic control, reduce body weight, and reduce the risk of major adverse cardiovascular events in people with atherosclerotic cardiovascular disease and type 2 diabetes (T2D). Methods and results STRIDE (NCT04560998) is a randomized, placebo-controlled, double-blind phase 3b trial evaluating 1 mg once-weekly subcutaneous semaglutide (GLP-1 RA) vs. placebo, in people with symptomatic PAD (Fontaine IIa claudication) and T2D. Eligible participants were ≥18 years, had haemodynamically stable PAD, had no planned intervention, and were not receiving a GLP-1 RA. The primary endpoint is change in maximum walking distance on a constant-load treadmill (CLT). Secondary endpoints include quality of life and cardiometabolic assessments. A total of 792 participants were randomized in 20 countries. Participants’ median age was 68 and median T2D duration 12 years. Risk factors included 25.6% current smokers, 87.9% with hypertension, and 42.7% with coronary heart disease. The mean BMI was 29.6 kg/m2 and the mean HbA1C was 7.3%. Participants exhibited baseline functional impairment with a median maximum walking distance of 186 m on a CLT.
Conclusion
STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA.
- Novo Nordisk A/S, Søborg, Denmark.
- Department of Vascular Surgery, Lillebaelt Hospital.
- Department of Regional Health Research, University of Southern Denmark, Denmark.
- Novo Nordisk GBS India, Bangalore, India.
- 1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders Landstrasse Clinic, Vienna, Austria.
ORCID-Profile: Marc P Bonaca, Kim Houlind, Joakim Nordanstig, Neda Rasouli, Harald Sourij, Subodh Verma
Förderung
- Novo Nordisk
Zitieren
APA
Bonaca, M. P., Catarig, A. M., Hansen, Y., Houlind, K., Ramesh, C. K., Ludvik, B., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2025). Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae071
Vancouver
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, et al. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae071
BibTeX
@article{Bonaca2025,
author = {Bonaca, Marc P and Catarig, Andrei-Mircea and Hansen, Yasemin and Houlind, Kim and Ramesh, Chethana Kalmady and Ludvik, Bernhard and Nordanstig, Joakim and Rasouli, Neda and Sourij, Harald and Verma, Subodh},
title = {Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvae071}
}
EUVIMED